Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. Whereas drug treatment has been shown to be superior in first-line treatment, data on allogeneic hematopoietic stem cell transplantation (allo SCT) as second-line therapy after imatinib failure are scarce. Using an interim safety analysis of the randomized German CML Study IV designed to optimize imatinib therapy by combination, dose escalation, and transplantation, we here report on 84 patients who underwent consecutive transplantation according to predefined criteria (low European Group for Blood and Marrow Transplantation [EBMT] score, imatinib failure, and advanced disease). Three-year survival after transplantation of 56 patients in chronic phase was 91% (median follow-up: 30 months). Tr......
POSTED 03/11/2010 at 11:02 AM --
|
Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia
(Source: Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents))...
POSTED 03/11/2010 at 07:49 AM --
|
Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia
In conclusion, determination of 1236T, C3435T, and G2677T MDR1 polymorphisms might be useful in response prediction
to therapy with imatinib in patients with CML.
Content Type Journal ArticleCategory Original paperDOI 10.1007/s12032-010-9456-9Authors
Ling-Na Ni, Nanjing Medical University Department of Hematology, Jiangsu Province Hospital, The First Affiliated Nanjing Medical University Hospital 300 Guangzhou Rd 210029 Nanjing ChinaJian-Yong Li, Nanjing Medical University Department of Hematology, Jiangsu Province Hospital, The First Affiliated Nanjing Medical University Hospital 300 Guangzhou Rd 210029 Nanjing ChinaKou-Rong Miao, Nanjing Medical University Department of Hematology, Jiangsu Province Hospital, The First Affiliated Nanjing Medical University Hospital 300 Guangzhou R......
POSTED 03/10/2010 at 10:02 AM --
|
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia. A study of the Spanish PETHEMA group.
Conclusions These results indicate the benefit of early intervention during imatinib therapy.
PMID: 20220063 [PubMed - as supplied by publisher] (Source: Haematologica)...
POSTED 03/09/2010 at 06:00 PM --
|
Key Cause Of Chronic Leukemia Progression Identified By Study
Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis. The study, led by cancer researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), indicates that chronic myeloid leukemia (CML) progresses when immature white blood cells lose a molecule called miR-328. Loss of the molecule traps the cells in a rapidly growing, immature state... (Source: Health News from Medical News Today)...
POSTED 03/08/2010 at 02:00 AM --
|
Study identifies key cause of chronic leukemia progression
Researchers have discovered a key reason why chronic myeloid leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis. The study indicates that CML progresses when immature white blood cells lose a molecule called miR-328 and this traps the cells in a rapidly growing, immature state. The research should provide a better understanding of the blast-crisis stage of CML, and it suggests a possible new treatment strategy for the disease. (Source: ScienceDaily Headlines)...
POSTED 03/05/2010 at 10:00 AM --
|
Successful Peripheral Blood Stem Cells Collection in Imatinib Pretreated and Nilotinib-Treated Chronic Myeloid Leukemia Patient
We report a case of a successful mobilization and harvest of the peripheral blood stem cells (PBSCs) in imatinib-pretreated and nilotinib treated 52-year-old woman diagnosed with Philadelphia chromosome-positive and BCR-ABL (b2a2) positive chronic phase CML in 2/2002. She failed interferon-alfa and imatinib treatment. She achieved her first complete molecular remission after 16 months of nilotinib treatment and later on was mobilized with filgrastim at a dose of 10 ug/kg/day applied subcutaneously once daily. The total number of 2.98×106 CD34+ cells/kg was harvested on the fourth day of the mobilization. The autologous graft of the stem cells was cryopreserved and tested for the residual disease: the FISH revealed negative results and the RT-PCR was positive (BCR-ABL/A......
POSTED 03/05/2010 at 07:48 AM --
|
Molecular diagnostics in chronic myeloid leukemia
Expert Opinion on Medical Diagnostics , March 2010, Vol. 4, No. 2, Pages 113-124. (Source: Expert Opinion: Expert Opinion on Medical Diagnostics)...
POSTED 03/05/2010 at 04:51 AM --
|
Overexpression of Apg-2 increases cell proliferation and protects from oxidative damage in BaF3-BCR/ABL cells.
Authors: Li C, Liu D, Yuan Y, Huang S, Shi M, Tao K, Feng W
Apg-2, a mammalian heat-shock protein belonging to the heat-shock protein 110 (Hsp110) family, was previously found to be overexpressed in BaF3-BCR/ABL cells that were treated with hydrogen peroxide (H2O2) through our comparative proteomics study. The expression of Apg-2 in chronic myelogenous leukemia (CML) cells and its role have not been investigated, forming the basis for this study. BaF3-MIGR1 and BaF3-BCR/ABL cell lines stably overexpressing Apg-2 were established and exposed to 50 microM H2O2 for 10 min. Western blot analysis of Apg-2 expression confirmed that H2O2 treatment significantly up-regulated Apg-2 expression. Apg-2 overexpression elevated BaF3-BCR/ABL cell proportions in S and G2/M phase, increased cell prolif......
POSTED 03/04/2010 at 04:59 PM --
|
Study identifies key cause of chronic leukemia progression
(Ohio State University Medical Center) Researchers have discovered a key reason why chronic myeloid leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis. The study indicates that CML progresses when immature white blood cells lose a molecule called miR-328 and this traps the cells in a rapidly growing, immature state. The research should provide a better understanding of the blast-crisis stage of CML, and it suggests a possible new treatment strategy for the disease. (Source: EurekAlert! - Medicine and Health)...
POSTED 03/03/2010 at 11:00 PM --
|
Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors
Authors: S Chu, T McDonald
& R Bhatia (Source: Leukemia)...
POSTED 03/03/2010 at 06:00 PM --
|
ARIAD Receives Orphan Drug Designations For Its Investigational Pan BCR-ABL Inhibitor, AP24534, In Chronic Myeloid Leukemia
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S... (Source: Cancer / Oncology News From Medical News Today)...
POSTED 03/03/2010 at 04:00 AM --
|
U.S. Food And Drug Administration (FDA) Sets 22 March For Oncologic Drugs Advisory Committee (ODAC) Meeting To Review OMAPRO™
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced that the U.S. Food and Drug Administration (FDA) has rescheduled the previously postponed Oncologic Drugs Advisory Committee (ODAC) meeting to 22 March 2010. The ODAC meeting will consider ChemGenex's application for OMAPRO™ (omacetaxine mepesuccinate) for the treatment of adults with chronic myeloid leukemia (CML) who have failed prior therapy with imatinib and who have developed the Bcr-Abl T315I mutation... (Source: Health News from Medical News Today)...
POSTED 03/03/2010 at 03:00 AM --
|
Molecular Monitoring of BCR-ABL Transcripts in Patients With Chronic Myelogenous Leukemia: Is High Sensitivity of Clinical Value?
Abstract Monitoring of disease response during treatment with tyrosine kinase inhibitors of patients with chronic myelogenous leukemia
dramatically changed after the introduction of real-time PCR, which allows quantification of BCR-ABL transcript levels with
high sensitivity and precision. However, its role in patients who have achieved complete cytogenetic response is not entirely
clear; incorrect interpretation of results could lead to unnecessary changes from an effective treatment. This review discusses
the current evidence regarding the benefits, uncertainties, and potential drawbacks of molecular monitoring in patients with
chronic myelogenous leukemia in chronic phase.
Content Type Journal ArticleDOI 10.1007/s11899-010-0046-xAuthors
Maxim Norkin, Wayne State U......
POSTED 03/03/2010 at 02:07 AM --
|
Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006
Conclusions:
The number of new patients arising in Shanghai increased from 2001 to 2006. There were still patients receiving hydroxyurea and IFN-alpha. As the first-line regime for CML, imatinib was less administered in Shanghai before, but has received considerable development and great responses since 2003. (Source: Journal of Experimental and Clinical Cancer Research)...
POSTED 03/02/2010 at 06:00 PM --
|
Chronic Myelogenous Leukemia
Learning Module - Join Brian Druker, MD; Elias Jabbour, MD; Neil P. Shah, MD, PhD; and Moshe Talpaz, MD, as they review the clinical implications of research on chronic myelogenous leukemia presented at the 2009 Hematology meeting. (Source: Clinical Care Options Oncology - Leukemia)...
POSTED 03/02/2010 at 06:00 AM --
|
p53 flow cytometry evaluation in leukemias: Correlation to factors affecting clinical outcome
p53 is a cell cycle checkpoint control protein that assesses DNA damage and acts as a transcription factor regulating genes, which control cell growth, DNA repair, and apoptosis. p53 mutations have been found in a wide variety of different cancers including flow cytometric assessment of p53 protein expression using anti-p53 monoclonal antibodies. We studied p53 protein expression by flow cytometry (FC) assay in 223 blood and/or bone marrow samples from 72 patients with chronic myeloid leukemia (CML): 54 in chronic phase (CML-CP), 7 in accelerated phase (CML-AP), and 11 in blastic phase (CML-BP); 64 patients with chronic lymphoid leukemia (CLL): (34 at diagnosis, 21 in previously treated, and 9 with Richter's syndrome); 44 patients with acute lymphoid leukemia (ALL): 36 at diagnosis and 8 i......
POSTED 03/01/2010 at 06:00 PM --
|
New Developments in Tyrosine Kinase Inhibitor Therapy for Newly Diagnosed Chronic Myeloid Leukemia.
Authors: le Coutre P, Schwarz M, Kim TD
The biology of chronic myeloid leukemia (CML) has enabled pioneering studies with targeted therapies. BCR-ABL inhibition with imatinib results in high levels of efficacy in patients with newly diagnosed CML in chronic phase (CP), but an estimated 35% of patients could benefit from more effective treatment. Several novel treatment strategies are being investigated in newly diagnosed CML-CP. These strategies include upfront treatment with next-generation tyrosine kinase inhibitors, such as dasatinib, nilotinib, or bosutinib, which also target BCR-ABL but with increased in vitro potency compared with imatinib, and possibly a reduced potential for resistance. Recent in vitro studies have shown that short-term exposure to dasatinib or continuous expos......
POSTED 03/01/2010 at 06:00 PM --
|
Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
In conclusion, results from this study highlight the potential of these novel series of PBOX compounds, alone or in sequential combination with flavopiridol, as an effective therapy against CML.
PMID: 20206141 [PubMed - as supplied by publisher] (Source: Biochemical Pharmacology)...
POSTED 03/01/2010 at 06:00 PM --
|
Rapid-onset central motor plasticity in multiple sclerosis
Conclusions: Despite motor impairment and CNS injury in patients with multiple sclerosis (MS), rapid-onset motor plasticity is comparable to that in healthy subjects. Compensation of MS-related CNS injury is unlikely to be constrained by insufficient rapid-onset neuroplasticity. (Source: Neurology)...
POSTED 03/01/2010 at 03:00 PM --
|
